MedicaidPrior AuthMedium impact
Cyramza (ramucirumab) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has established a new prior authorization policy for Cyramza (ramucirumab), an oncology drug used for treating various cancers including esophageal, colorectal, lung, gastric, and hepatocellular carcinomas. The policy requires prior authorization for all Cyramza treatments with specific clinical criteria that must be met for each cancer indication.
Action Required
Before March 1, 2026: Billing team must update system to require prior authorization for all Cyramza (ramucirumab) treatments for Humana Medicaid Indiana patients. Providers must ensure clinical documentation meets specific criteria for each cancer indication (esophageal, colorectal, NSCLC, gastric, hepatocellular carcinoma) including treatment line, combination therapies, and biomarker requirements where applicable. Visit www.humana.com/PAL for medical billing codes and preauthorization requirements. Claims will be denied without proper prior authorization.